Pharmaceuticals, Biotechnology and Life Sciences
Results from a phase 2 randomized trial study published today in Annals of Internal Medicine DUARTE, Calif.–(BUSINESS WIRE)–#CityofHope–Patients who underwent…
BETHESDA, Md.–(BUSINESS WIRE)–#AD–India Globalization Capital, Inc. (NYSE American: IGC) today announced financial results for the quarter ended December 31, 2019,…
Phase 2 CMV vaccine dose-confirmation study more than sixty percent enrolled mRNA-1189 to prevent infectious mononucleosis and Epstein-Barr virus (EBV)…
mRNA-3704 is Moderna’s first rare disease program to enter clinical studies CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage…
Data from the COSMIC-021 trial will be presented on Thursday, February 13, 2020 at the American Society of Clinical Oncology’s…
– Merck Option Agreement Expires – CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–$KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical…
SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs,…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create…
NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (“Revance”) (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic…
NEW YORK–(BUSINESS WIRE)–Schrödinger, Inc. (the “Company”) (Nasdaq: SDGR), whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for…